KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Prepaid Assets (2018 - 2025)

Historic Prepaid Assets for Esperion Therapeutics (ESPR) over the last 8 years, with Q3 2025 value amounting to $4.4 million.

  • Esperion Therapeutics' Prepaid Assets fell 6941.65% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $4.4 million, marking a year-over-year decrease of 6941.65%. This contributed to the annual value of $4.2 million for FY2024, which is 781.01% down from last year.
  • Latest data reveals that Esperion Therapeutics reported Prepaid Assets of $4.4 million as of Q3 2025, which was down 6941.65% from $5.4 million recorded in Q2 2025.
  • Esperion Therapeutics' Prepaid Assets' 5-year high stood at $34.2 million during Q1 2021, with a 5-year trough of $4.2 million in Q4 2024.
  • Its 5-year average for Prepaid Assets is $9.6 million, with a median of $9.2 million in 2022.
  • As far as peak fluctuations go, Esperion Therapeutics' Prepaid Assets soared by 20088.96% in 2021, and later crashed by 6941.65% in 2025.
  • Over the past 5 years, Esperion Therapeutics' Prepaid Assets (Quarter) stood at $11.2 million in 2021, then fell by 11.7% to $9.9 million in 2022, then tumbled by 54.32% to $4.5 million in 2023, then dropped by 7.81% to $4.2 million in 2024, then rose by 6.09% to $4.4 million in 2025.
  • Its last three reported values are $4.4 million in Q3 2025, $5.4 million for Q2 2025, and $4.8 million during Q1 2025.